Latest News

Photocure will present its fourth quarter report on Thursday 27 February 2020 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET).

Oslo, Norway February 14, 2020, Photocure ASA (OSE: PHO) is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted US Patent No. 10,556,010 covering the use of Blue Light Cystoscopy (BLC^®) with Hexvix as neoadjuvant* therapy in the treatment of bladder cancer in patients who are scheduled for a cystectomy.

The benefits of Blue light technology in the detection of Bladder Cancer are explained in detail on Fox News in a news topic featuring an interview with Dr. Sia Daneshmand on January 20, 2020.

Oslo, Norway, 31 December 2019.

Participants in the Photocure ASA's share option program have on 31 December 2019 exercised a total of 150,168 options. The share options are exercised at expiry on 31 December 2019 and at a strike price of NOK 32.78. Each option gives a right to receive one share in the company. The share options are described in note 7 in Photocure's annual financial statements for 2018.

Oslo, Norway December 19, 2019: Photocure ASA (Photocure, PHO: OSE) proudly announces that Cevira® received the prestigious Fierce Innovation Award (FIA), on December 18, 2019.

Use of flexible Blue Light Cystoscopy at the first follow-up after TURBT* reduced the risk of tumor recurrence by 33% compared to white light alone. The randomized controlled multi-center study that included 699 bladder cancer patients at 3 hospitals in Denmark is now published in Urology, The Gold Journal.

Oslo, Norway, December 6, 2019 - Photocure ASA (OSE: PHO) will be presenting at the DNB Nordic Healthcare Conference in Oslo on December 12.

Oslo, Norway, November 29, 2019 - Photocure ASA (OSE: PHO) will be presenting at the Nordic-American Life Science Conference in New York on December 5.

Use of flexible Blue Light Cystoscopy at the first follow-up after TURBT* reduced the risk of tumor recurrence by 33% compared to white light alone. Randomized controlled multi-center study with 699 bladder cancer patients presented at Danish Urological Society meeting.

Oslo, Norway, 7 November 2019: Photocure ASA (OSE:PHO), today reported a revenue growth of 42% in local currency for the U.S. market in the third quarter of 2019, contributing to Hexvix/Cysview revenues of NOK 51.1 million (Q3 2018: NOK 43.5) and an EBITDA of NOK 8.3 million (NOK -3.1 million). The company entered into a license agreement with Asieris for the global commercialization of Cevira® and reiterates the significant revenue growth and profit opportunities in the U.S. market.

CMS final rule expands complexity adjustment for Hospital Outpatient from two to three procedure codes and increases the reimbursement due to the complexity adjustment for these procedures by $92 compared to 2019.

Photocure will present its third quarter report on Thursday 7 November 2019 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET).

Oslo, Norway, October 28th, 2019: today Photocure ASA announced highlights from the BLADDR 2019 congress, October 25-26 in Paris, France. The BLADDR congress is solely focused on bladder cancer and attracts bladder cancer experts from all over the world.

Successful experience with Blue Light Flexible Cystoscopy and Bladder Tumor destruction with Diode Laser in Outpatient Clinic.

Oslo, Norway, 19 September 2019, Photocure ASA (OSE: PHO) management will be presenting at the Norne Securities Vekst & Verdi Aksjeseminar in Vilnius, Lithuania on September 20 at 14:25 EEST/13:25 CEST.

Oslo, Norway, 3 September 2019, - Photocure ASA (OSE: PHO) management will be presenting at the 21st Annual Healthcare Conference to investors and industry peers in New York (US) on September 9 at 10:50 EDT. The conference is sponsored by H.C. Wainwright & Co. The presentation will be posted on www.photocure.com when held on September 9, 2019. 

Oslo, Norway, 7 August 2019: Photocure ASA (OSE:PHO), today reported a revenue growth of 41% in local currency for the U.S. market in the second quarter of 2019, contributing to Hexvix/Cysview revenues of NOK 52.1 million (Q2 2018: NOK 42.4) and a recurring EBITDA of NOK -2.6 million (NOK 0.7 million). The company continues to receive strong endorsement for the use of Blue Light Cystoscopy (BLC) with Cysview and reiterates the significant revenue growth and profit opportunities in the U.S. market.

Photocure will present its second quarter and first half year report on Wednesday 7 August 2019 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET).